ACAD
33.79
-0.92
-2.65%
AEMD
2.193
+0.073
+3.4198%
APRI
1.17
+0.01
+0.8534%
ARNA
1.4
+0.01
+0.72%
ATEC
2.01
+0.03
+1.52%
CNAT
8.36
+0.84
+11.17%
CRXM
0.2
0.00
0.00%
CYTX
1.06
0.00
0.00%
DXCM
75.86
+0.92
+1.23%
GNMK
13.06
+0.21
+1.59%
HALO
13.99
+0.03
+0.21%
ILMN
182.97
+1.47
+0.81%
INNV
0.094
+0.001
+0.967%
INO
6.69
-0.1
-1.47%
ISCO
1.75
+0.12
+7.36%
ISIS
57.56
0.00
0.00%
LGND
109.505
+0.605
+0.556%
LPTN
2.93
0.00
0.00%
MBVX
2.07
-0.01
-0.4663%
MEIP
1.54
-0.02
-1.2692%
MNOV
5.92
+0.35
+6.28%
MRTX
4.65
+0.05
+1.09%
MSTX
0.138
+0.002
+1.6260%
NBIX
53.58
-0.04
-0.07%
NUVA
73.56
-3.38
-4.39%
ONCS
1.18
+0.02
+1.72%
ONVO
2.849
+0.069
+2.4928%
OREX
3.19
+0.09
+2.90%
OTIC
13.65
+0.45
+3.41%
QDEL
24.13
-0.37
-1.51%
RCPT
231.96
0.00
0.00%
RGLS
1.475
+0.025
+1.724%
RMD
71.79
+0.85
+1.20%
SPHS
2.588
-0.012
-0.4500%
SRNE
1.975
+0.075
+3.947%
TROV
0.914
+0.037
+4.231%
VICL
2.332
-0.028
-1.1991%
VOLC
18
0.00
0.00%
ZGNX
10.9
+0.1
+0.93%
ACAD
33.79
-0.92
-2.65%
AEMD
2.193
+0.073
+3.4198%
APRI
1.17
+0.01
+0.8534%
ARNA
1.4
+0.01
+0.72%
ATEC
2.01
+0.03
+1.52%
CNAT
8.36
+0.84
+11.17%
CRXM
0.2
0.00
0.00%
CYTX
1.06
0.00
0.00%
DXCM
75.86
+0.92
+1.23%
GNMK
13.06
+0.21
+1.59%
HALO
13.99
+0.03
+0.21%
ILMN
182.97
+1.47
+0.81%
INNV
0.094
+0.001
+0.967%
INO
6.69
-0.1
-1.47%
ISCO
1.75
+0.12
+7.36%
ISIS
57.56
0.00
0.00%
LGND
109.505
+0.605
+0.556%
LPTN
2.93
0.00
0.00%
MBVX
2.07
-0.01
-0.4663%
MEIP
1.54
-0.02
-1.2692%
MNOV
5.92
+0.35
+6.28%
MRTX
4.65
+0.05
+1.09%
MSTX
0.138
+0.002
+1.6260%
NBIX
53.58
-0.04
-0.07%
NUVA
73.56
-3.38
-4.39%
ONCS
1.18
+0.02
+1.72%
ONVO
2.849
+0.069
+2.4928%
OREX
3.19
+0.09
+2.90%
OTIC
13.65
+0.45
+3.41%
QDEL
24.13
-0.37
-1.51%
RCPT
231.96
0.00
0.00%
RGLS
1.475
+0.025
+1.724%
RMD
71.79
+0.85
+1.20%
SPHS
2.588
-0.012
-0.4500%
SRNE
1.975
+0.075
+3.947%
TROV
0.914
+0.037
+4.231%
VICL
2.332
-0.028
-1.1991%
VOLC
18
0.00
0.00%
ZGNX
10.9
+0.1
+0.93%
Home » Archive by Category

Xconomy

The Xconomy Immuno-Oncology Resource: A Mid-ASH T Cell Update

December 5, 2016 – 4:35 am

[Updated, 12/5/16, 4 p.m. See below.] If you’re following cancer immunotherapy, you might feel a bit swamped by this week’s wave of clinical data from experimental programs that turn…

[[Click headline to continue reading.]]

This Week in Drug Pricing and Post-Election Healthcare Policy News

December 2, 2016 – 7:50 am

Healthcare news has been coming fast and furious in the fallout of the election, particularly this week. Read on below for the latest on the 21st Century Cures Act, the Trump Administration’s latest…

[[Click headline to continue reading.]]

Bio Roundup: CAR-T Ups & Downs, Lilly’s Failure, Myeloma & More

December 2, 2016 – 7:00 am

We’ve packed some extra stuffing into the roundup this week to account for some burnt turkey delivered by biopharma in the few days before Thanksgiving—starting with Eli Lilly’s failed gamble…

[[Click headline to continue reading.]]

Brushing Aside Critics, House Votes in Landslide for Cures Act

November 30, 2016 – 5:16 pm

By a 392 to 26 vote, the U.S. House of Representatives has passed the omnibus healthcare legislation called the 21st Century Cures Act, bringing new funding for top Obama administration health…

[[Click headline to continue reading.]]

Trump Tabs Fiscal, Social Conservatives To Run U.S. Health Agencies

November 29, 2016 – 2:04 pm

Two big pieces of the Trump healthcare puzzle have fallen into place. The President-elect’s transition team has nominated Georgia Republican congressman Tom Price to be Health and Human…

[[Click headline to continue reading.]]

Should We Rewrite the Human Genome?

November 28, 2016 – 4:00 am

Scientists are engineering a new living thing: a radically modified version of the lowly bacterium E. coli. In an article in Science from August, researchers at Harvard University described an…

[[Click headline to continue reading.]]

Precision Medicine In Trump Era? California Presses Own Modest Program

November 22, 2016 – 8:34 am

[Updated, 11/22/16, 5:42 p.m. See below.] Among the many questions swirling around the incoming Trump administration is the fate of ambitious biomedical science projects that require federal funding….

[[Click headline to continue reading.]]

Bio Roundup: Trump’s Rx Silence, PCSK9 News, Amgen’s Migraines & More

November 18, 2016 – 4:30 am

Speculation swirled this week around the incoming U.S. president’s intent to make good on his angry campaign rhetoric on drug prices, while the Associated Press reported that…

[[Click headline to continue reading.]]

How to Lower Drug Prices, Improve Care, and Save Pharma

November 16, 2016 – 10:52 pm

I recently received a note from a longtime friend who questioned me on the issue of pharma pricing. I answered with the always-reliable…

[[Click headline to continue reading.]]

Bio Roundup: Trump’s Triumph, Election Fallout, CRISPR Arguments & More

November 11, 2016 – 1:00 am

The presidential election ended with Donald Trump’s stunning victory and Republican retention of the House and Senate. Now, the U.S. healthcare sector will try to figure out what it all means. Drug…

[[Click headline to continue reading.]]